Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium
Pres. Biden recently warned about China's dominance when it comes to lithium demand, stating, "if we don't get moving, they're going to eat our lunch." One junior mining company in South America is looking to become a strong link in the lithium supply chain due to a monster acquisition.
Get the full scoop on this investment opportunity
Michael L. Levitz, insider at Anika Therapeutics
Michael L. Levitz Insider Alerts

Get notified the next time Michael L. Levitz buys or sells Anika Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Michael L. Levitz Insider Information

On August 10, 2020, Michael Levitz was appointed Executive Vice President, Chief Financial Officer and Treasurer. Prior to joining Anika, Mr. Levitz served as Senior Vice President, Chief Financial Officer and Treasurer of Insulet Corporation, a global innovative medical device and drug delivery company. From 2009 to 2015, he was the Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation, a global provider of medical guidance, diagnostic imaging and threat detection equipment. Previously, during his seven years with Hologic, Inc. and Cytyc Corporation (which merged with Hologic in October 2007), Mr. Levitz served in various capacities including Vice President and Corporate Controller. He began his career in the high technology audit practice at Arthur Andersen LLP. In 2011, he was a finalist for the Boston Business Journal’s Chief Financial Officer of the Year award.

Mr. Levitz earned his Bachelor of Arts in Business Economics, with emphasis in Accounting, from the University of California Santa Barbara and is a certified public accountant.

What is Michael L. Levitz's salary?

As the CFO of Anika Therapeutics, Inc., Mr. Levitz earned a total compensation package of $1,857,960.00 in 2020. Mr. Levitz earned a salary of $173,077.00, a bonus of $73,601.00, stock awards of $799,971.00, options awards of $799,993.00, and other compensation of $11,318.00.

How do I contact Michael L. Levitz?

The corporate mailing address for Mr. Levitz and other Anika Therapeutics executives is 32 WIGGINS AVENUE, BEDFORD MA, 01730. Anika Therapeutics can also be reached via phone at (781) 457-9000 and via email at [email protected]

Has Michael L. Levitz been buying or selling shares of Anika Therapeutics?

Michael L. Levitz has not been actively trading shares of Anika Therapeutics in the last ninety days. Most recently, on Wednesday, August 11th, Michael L. Levitz bought 2,850 shares of Anika Therapeutics stock. The stock was acquired at an average cost of $40.21 per share, with a total value of $114,598.50.

Who are Anika Therapeutics' active insiders?

Anika Therapeutics' insider roster includes John Hennemann, III (Director), Raymond Land (Director), Michael Levitz (CFO), Michael Levitz (CFO), and Michael Levitz (CFO).

Are insiders buying or selling shares of Anika Therapeutics?

In the last year, Anika Therapeutics insiders bought shares 2 times. They purchased a total of 4,850 shares worth more than $200,318.50. In the last year, insiders at the biotechnology company sold shares 1 times. They sold a total of 2,000 shares worth more than $85,200.00. The most recent insider tranaction occured on August, 11th when CFO Michael L Levitz bought 2,850 shares worth more than $114,598.50. Insiders at Anika Therapeutics own 1.1 % of the company.

Information on this page was last updated on 8/11/2021.

Michael L. Levitz Insider Trading History at Anika Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/11/2021Buy2,850$40.21$114,598.50View SEC Filing Icon  
See Full Table

Michael L. Levitz Buying and Selling Activity at Anika Therapeutics

This chart shows Michael L Levitz's buying and selling at Anika Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Anika Therapeutics Company Overview

Anika Therapeutics logo
Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.
Read More

Today's Range

Now: $39.47
Low: $39.08
High: $40.50

50 Day Range

MA: $40.96
Low: $38.20
High: $45.03

2 Week Range

Now: $39.47
Low: $32.30
High: $48.37

Volume

80,364 shs

Average Volume

76,688 shs

Market Capitalization

$569.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.15
One Pot Stock Could Skyrocket With Looming Interstate Sales
A new bill in Congress would decriminalize marijuana nationally by removing cannabis from the federal government’s list of controlled substances. The law would also allow one established Seattle cannabis company to market across state lines for the first time – potentially setting off a bidding war that could blast this stock into the stratosphere!
Find Out Why This Could Be the #1 Pot Stock